| Item type: | Article | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journal or Publication Title: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | ||||||||||||||||||||||||||||||||||||||||||||||||
| Publisher: | AMER SOC CLINICAL ONCOLOGY | ||||||||||||||||||||||||||||||||||||||||||||||||
| Place of Publication: | ALEXANDRIA | ||||||||||||||||||||||||||||||||||||||||||||||||
| Volume: | 24 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Number of Issue or Book Chapter: | 31 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Page Range: | pp. 5060-9 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Date: | 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Institutions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Identification Number: |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Classification: |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Keywords: | ALLOGENEIC BONE-MARROW; TUMOR-IMMUNOTHERAPY; VIVO PERSISTENCE; LYMPHOCYTES; REGRESSION; CLONES; CANCER; DONOR; INTERLEUKIN-2; SURVIVAL; | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Published | ||||||||||||||||||||||||||||||||||||||||||||||||
| Refereed: | Yes, this version has been refereed | ||||||||||||||||||||||||||||||||||||||||||||||||
| Created at the University of Regensburg: | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||
| Item ID: | 14492 |
Web of ScienceAbstract
Purpose The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients. Patients and Methods Eleven HLA-A2(+) patients with metastatic melanoma received ...
Abstract
Purpose The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients. Patients and Methods Eleven HLA-A2(+) patients with metastatic melanoma received at least three intravenous infusions of Melan-A -specific CTL at 2-week intervals. CTL were generated by four rounds of in vitro stimulation of purified CD8(+) peripheral blood lymphocytes with autologous dendritic cells pulsed with an HLA-A2 binding Melan-A peptide. Each T-cell infusion was accompanied by a 6-day course of low-dose interleukin-2. Results A total of 52 T-cell infusions were administered, averaging 2.1 x 10(8) Melan-A -specific CTL per infusion. Clinical adverse effects were mild and consisted of chills and low-grade fever in seven of 11 patients. Clinical and immunologic responses revealed an antitumor response in three of 11 patients ( one complete regression, one partial regression, one mixed response), an elevated frequency of circulating Melan-A tetramer(+) T cells up to 2 weeks in all the patients with a maximal frequency of 2% of total CD8(+) T cells, an increase in eosinophils to up to 50% in seven of 11 patients, and a selective loss of Melan-A expression in lymph node metastases in two evaluated patients after T-cell transfer. Conclusion Our data indicate that the adoptive transfer of antigen-specific T cells in melanoma patients can induce clinical tumor-specific immune responses without major adverse effects.
Metadata last modified: 29 Sep 2021 07:37
Altmetric